Literature DB >> 9140770

Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.

D L Warner1, T G Burke.   

Abstract

The well documented hydrolysis of the alpha-hydroxy-delta-lactone ring moiety in camptothecin and related analogues is routinely monitored using high-performance liquid chromatography (HPLC). Previous HPLC separations of the lactone and carboxylate forms of camptothecins have often required mobile phases containing three to four components; ion-pairing reagent to provide adequate retention of the carboxylate form of the drug; buffer to control the ionic strength and pH of the mobile phase; acetonitrile to control the retention of the lactone form and, in some instances, sodium dodecyl sulfate to reduce peak tailing. Because of the complexity of the mobile phases employed, development of these assays can be a laborious process, requiring re-optimization for each new analogue. In this study, we have developed a simple HPLC methodology for the simultaneous separation of the lactone and carboxylate forms of numerous camptothecin analogues. The mobile phase employed includes only triethylamine acetate (TEAA) buffer and acetonitrile. In this application, triethylamine serves multiple roles; as the ion-pairing reagent, as a masking agent for underivatized silanols and as the major buffer component. By altering only the composition of TEAA buffer with respect to acetonitrile, method development becomes a more streamlined and time efficient process. In this publication, we present the simultaneous separation of the lactone and carboxylate forms of camptothecin and four related analogues, namely, topotecan, GI147211, 10-aminocamptothecin and the CPT-11-SN-38 drug-metabolite pair. It is proposed that this new mobile phase, consisting of only triethylamine acetate buffer and acetonitrile, can be used for the analysis of the several camptothecin derivatives presently in clinical trials as well as the numerous other analogues in preclinical development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140770     DOI: 10.1016/s0378-4347(96)00426-4

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  12 in total

Review 1.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

2.  Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.

Authors:  Arup Bhattacharya; Mukund Seshadri; Steven D Oven; Károly Tóth; Mary M Vaughan; Youcef M Rustum
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

3.  Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Daniel Bar-Shalom; André Huss Eriksson; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-11-22       Impact factor: 3.246

4.  A method to determine the incorporation capacity of camptothecin in liposomes.

Authors:  Ann Mari Saetern; Gøril Eide Flaten; Martin Brandl
Journal:  AAPS PharmSciTech       Date:  2004-06-17       Impact factor: 3.246

5.  Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

Authors:  Rami G Azrak; Shousong Cao; Farukh A Durrani; Karoly Toth; Arup Bhattacharya; Youcef M Rustum
Journal:  Cancer Lett       Date:  2011-08-06       Impact factor: 8.679

6.  Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

Authors:  Shousong Cao; Farukh A Durrani; Youcef M Rustum; Y Eugene Yu
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-12       Impact factor: 3.333

7.  Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.

Authors:  Carles Monterrubio; Sonia Paco; Monica Vila-Ubach; Eva Rodríguez; Romina Glisoni; Cinzia Lavarino; Paula Schaiquevich; Alejandro Sosnik; Jaume Mora; Angel M Carcaboso
Journal:  Pharm Res       Date:  2015-03-14       Impact factor: 4.200

8.  Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model.

Authors:  Piyun Chao; Manjeet Deshmukh; Hilliard L Kutscher; Dayuan Gao; Sujata Sundara Rajan; Peidi Hu; Debra L Laskin; Stanley Stein; Patrick J Sinko
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

9.  A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity.

Authors:  Manjeet Deshmukh; Piyun Chao; Hilliard L Kutscher; Dayuan Gao; Patrick J Sinko
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

10.  The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

Authors:  Lluis A Lopez-Barcons; Junhong Zhang; Gunching Siriwitayawan; Thomas G Burke; Roman Perez-Soler
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.